26 June
Here is our weekly roundup on the latest research and scientific efforts against the coronavirus.
Gilead Sciences
Gilead Sciences is planning to begin testing an inhaled formulation of Remdesivir – given via a nebulizer - to volunteers in a phase 1 trial due to begin in August.
Read more here.
GSK and Clover Biopharma
GSK and Clover Biopharma are beginning phase 1 trials of their covid-19 vaccine candidate, SCB-2019. Following promising preclinical results in animal models, human testing has begun, with results due next month. Plans are being made for a phase 2b/3 efficacy trial later in the year.
Sanofi
In September, Sanofi will begin clinical testing on the recombinant protein-based vaccine, which uses GSK’s AS03 adjuvant and is based on Sanofi’s baculovirus expression system. They hope to begin phase 3 trials for that vaccine towards the end of year or early 2021, with a goal of having the vaccine fully licensed by June.
Read more here.
Evelo Biosciences
Evelo Biosciences has recently announced that its lead inflammation product candidate, EDP1815, will be included in the TACTIC-E clinical trial, evaluating the safety and efficacy of certain experimental therapies for treating complications associated with hospitalised patients with covid-19.
Read more here.
FDA & COVID-19 Diagnostics Evidence Accelerator
The FDA has joined the covid-19 Diagnostics Evidence Accelerator, in analysing real-world data and evaluating the performance of both PCR and antibody tests, the goal being to speed up the pace of covid-19 diagnostics testing.
Read more here.
Keep up to date on the response from the chemical industry and the scientific community to the COVID-19 (coronavirus) outbreak. SCI will be covering key coronavirus research and reporting news from trusted sources so that you have the coronavirus latest.
Visit Blog